Knapp, Martin 
ORCID: 0000-0003-1427-0215, King, Derek ORCID: 0000-0002-2408-4558, Romeo, Renée, Adams, Jessica, Baldwin, Ashley, Ballard, Clive, Banerjee, Sube, Barber, Robert, Bentham, Peter, Brown, Richard G., Burns, Alistair, Dening, Tom, Findlay, David, Holmes, Clive, Johnson, Tony, Jones, Robert, Katonal, Cornelius, Lindesay, James, Macharouthu, Ajay, McKeith, Ian, McShane, Rupert, O'Brien, John T., Phillips, Patrick P. J., Sheehan, Bart and Howard, Robert
(2016)
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial).
International Journal of Geriatric Psychiatry.
ISSN 0885-6230
|
PDF
- Published Version
Available under License Creative Commons Attribution. Download (786kB) | Preview |
Abstract
Objective Most investigations of pharmacotherapy for treating Alzheimer’s disease focus on patients with mild-to-moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzheimer’s disease patients. Methods Cost-effectiveness analysis was based on a 52-week, multicentre, double-blind, placebo-controlled, factorial clinical trial. A total of 295 community-dwelling patients with moderate/severe Alzheimer’s disease, already treated with donepezil, were randomised to: (i) continue donepezil; (ii) discontinue donepezil; (iii) discontinue donepezil and start memantine; or (iv) continue donepezil and start memantine. Results Continuing donepezil for 52 weeks was more cost-effective than discontinuation, considering cognition, activities of daily living and health-related quality of life. Starting memantine was more cost-effective than donepezil discontinuation. Donepezil-memantine combined is not more cost-effective than donepezil alone. Conclusions Robust evidence is now available to inform clinical decisions and commissioning strategies so as to improve patients’ lives whilst making efficient use of available resources. Clinical guidelines for treating moderate/severe Alzheimer’s disease, such as those issued by NICE in England and Wales, should be revisited.
| Item Type: | Article |
|---|---|
| Official URL: | http://onlinelibrary.wiley.com/journal/10.1002/(IS... |
| Additional Information: | © 2016 The Authors © CC BY 4.0 |
| Divisions: | Care Policy and Evaluation Centre |
| Subjects: | R Medicine > RA Public aspects of medicine |
| Date Deposited: | 06 Sep 2016 15:34 |
| Last Modified: | 28 Nov 2024 20:09 |
| Projects: | G0600989 |
| Funders: | National Institute for Health Research, South London and Maudsley NHS Foundation Trust, King's College London, Medical Research Council |
| URI: | http://eprints.lse.ac.uk/id/eprint/67601 |
Actions (login required)
 |
View Item |
Download Statistics
Download Statistics